Spectral AI names Prof. Paul Chadwick, Former CEO of the Royal College of Podiatry UK, as Senior Executive for UK and EMEA

DALLAS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- *Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”),* an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Prof. Paul Chadwick as Executive Vice President of the Company’s United Kingdom subsidiary. Prof. Chadwick is an experienced clinical scientist and wound care key opinion leader (KOL) with an impressive body of work including a substantial and impactful publication record, particularly in the domain of diabetic wound management. He will be responsible for the international market expansion of the Company’s DeepView^® wound imaging technology in the United Kingdom, Europe, Middle East and Africa (EMEA), all of which are geographic areas where Prof. Chadwick has extensive clinical networks, significant experience and has enjoyed previous successes.“Paul brings over fifteen years of invaluable expertise in the medical devices and technology sectors to our team. The Royal College of Podiatry is an extremely prestigious and important organization where Paul most recently served for over six years in senior executive capacities, including CEO. We are highly confident that his addition will significantly enhance our efforts in advancing the widespread adoption of the DeepView^® System,” said Niko Pagoulatos, the Company’s COO. “Spectral AI continues to strengthen its leadership team and Paul’s experience in diabetic foot ulcers and clinical wound management will contribute to our growth and enhance our capacity to innovate.”

Prof. Chadwick’s impressive journey stretches across clinical, academic and business disciplines. In his previous roles at the Royal College of Podiatry, Prof. Chadwick led all the clinical, educational and financial aspects of the organization. In addition, he has held multiple leadership positions such as consultant podiatrist at The National Health Service (NHS), and Managing Director at Curativo Wound Care Consultancy, where he has served companies such as 3M, Molnlycke Health Care, Smith & Nephew, Advancis, Thornton & Ross, Essity and many others. In his capacity as a prominent authority in wound care, Prof. Chadwick fulfills critical roles on advisory boards and exemplifies best practices in the field. Furthermore, he generously imparts his knowledge as an adjunct professor at Birmingham City University, where he teaches in the Health and Life Sciences Department.

Prof. Chadwick said, “Coming from a traditional wound care background with an emphasis on DFU and other chronic wounds, and having collaborated with leading commercial organizations in the wound care arena at a national and global level, with a focus on EMEA, I am delighted to contribute to Spectral AI’s mission and success, and I believe that the DeepView^® System represents the future of wound healing management. As we move forward, this technology has the potential to transform patient wound care at multiple levels.”

Prof. Chadwick earned his Ph.D. with a thesis on aspects of painful diabetic neuropathy at the University of Salford. He earned his M.Sc. with a focus on foot ulceration from Manchester Metropolitan University and holds an undergraduate degree in Science Honors from the University of Brighton.

*About Spectral AI*

Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown^®” with its DeepView^® System. DeepView^® is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of substantially exceeding the current standard of care in the future, DeepView^® is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView^®, visit www.spectral-ai.com.

*Forward Looking Statements*

Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.

These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.

Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.

*Contacts:*

*Investors:*
*Spectral AI, Inc.*
Christine Marks
VP Marketing and Commercialization
ir@spectral-ai.com   

*The Equity Group*
Devin Sullivan
Managing Director
dsullivan@equityny.com 

Conor Rodriguez
Analyst
crodriguez@equityny.com 

*Media:*
* Russo Partners*
David Schull
Russo Partners
(858) 717-2310
david.schull@russopartnersllc.com 

Guillermo Ruiz, M.D., Ph.D.
Russo Partners
(646) 218-4604
guillermo.ruiz@russopartnersllc.com